SE422941B - Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar - Google Patents

Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar

Info

Publication number
SE422941B
SE422941B SE7603931A SE7603931A SE422941B SE 422941 B SE422941 B SE 422941B SE 7603931 A SE7603931 A SE 7603931A SE 7603931 A SE7603931 A SE 7603931A SE 422941 B SE422941 B SE 422941B
Authority
SE
Sweden
Prior art keywords
preparation
analogy procedure
benzazepine compounds
tetracyclic
pyrido
Prior art date
Application number
SE7603931A
Other languages
English (en)
Swedish (sv)
Other versions
SE7603931L (sv
Inventor
Der Burg W J Van
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE422941(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of SE7603931L publication Critical patent/SE7603931L/xx
Publication of SE422941B publication Critical patent/SE422941B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SE7603931A 1975-04-05 1976-04-02 Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar SE422941B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (2)

Publication Number Publication Date
SE7603931L SE7603931L (sv) 1976-10-06
SE422941B true SE422941B (sv) 1982-04-05

Family

ID=19823518

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7603931A SE422941B (sv) 1975-04-05 1976-04-02 Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar

Country Status (17)

Country Link
US (1) US4062848A (cs)
JP (1) JPS5942678B2 (cs)
BE (1) BE840362A (cs)
CA (1) CA1076571A (cs)
CH (1) CH622261A5 (cs)
DE (1) DE2614406A1 (cs)
DK (1) DK142498B (cs)
ES (2) ES446634A1 (cs)
FI (1) FI62087C (cs)
FR (1) FR2305986A1 (cs)
GB (1) GB1543171A (cs)
HU (1) HU179401B (cs)
IE (1) IE42969B1 (cs)
LU (1) LU74680A1 (cs)
NL (2) NL189199C (cs)
SE (1) SE422941B (cs)
ZA (1) ZA761756B (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
CA2026925A1 (en) * 1989-10-05 1991-04-06 Hiroshi Fukumi Tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
EP0539164A1 (en) * 1991-10-23 1993-04-28 Sankyo Company Limited Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
PT1067934E (pt) * 1998-04-02 2004-03-31 Akzo Nobel Nv Solucao anti-depressiva liquida oral
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
CN1356903A (zh) * 1999-04-19 2002-07-03 特瓦制药工业有限公司 含哌嗪环化合物的新型合成和结晶方法
EP1178805A4 (en) * 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
CA2370389A1 (en) 1999-04-19 2000-10-26 Ben-Zion Dolitzky Novel synthesis of piperazine ring
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
WO2001025185A1 (fr) * 1999-09-30 2001-04-12 Sumika Fine Chemicals Co., Ltd. Procede de production de derive de piperazine
WO2001038329A1 (fr) * 1999-11-24 2001-05-31 Sumika Fine Chemicals Co., Ltd. Cristaux de mirtazapine anhydre et leur procede d'obtention
AU6474200A (en) 1999-12-13 2001-06-18 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound
CN1223349C (zh) * 2000-01-19 2005-10-19 阿克佐诺贝尔公司 用于治疗抑郁症和相关病症的包括米氮平的联合用药物
WO2001058453A1 (en) 2000-02-11 2001-08-16 Akzo Nobel N.V. The use of mirtazapine for the treatment of sleep disorders
IN190478B (cs) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
JP2005501808A (ja) 2001-03-01 2005-01-20 テバ ファーマシューティカル インダストリーズ リミティド ミルタザピン中間体の製造方法
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
WO2006020817A1 (en) * 2004-08-13 2006-02-23 Omeros Corporation Novel serotonin receptor ligands and their uses thereof
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2006022182A1 (ja) * 2004-08-24 2006-03-02 Sumitomo Chemical Company, Limited ２－（４－メチル－２－フェニルピペラジン－１－イル）－３－シアノピリジンの製造方法
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
ZA200804860B (en) * 2005-11-14 2009-11-25 Sumitomo Chemical Co Method for producing 2-(4-methyl-2-phenylpiperazin-1-yl)pyridine-3-methanol
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
EP1993556A1 (en) * 2006-03-06 2008-11-26 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
CN101679420B (zh) * 2007-04-11 2014-05-14 默沙东有限责任公司 一种制备对映体纯的苯并氮杂*的方法
AR066005A1 (es) 2007-04-11 2009-07-15 Organon Nv Un metodo para la preparacion de un enantiomero de una benzazepina tetraciclica
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
EP2344498A1 (en) 2008-10-22 2011-07-20 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (cs) * 1966-03-12
NL7202963A (cs) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
JPS5942678B2 (ja) 1984-10-16
LU74680A1 (cs) 1976-11-11
NL940007I2 (nl) 1994-10-17
IE42969L (en) 1976-10-05
DK142498B (da) 1980-11-10
BE840362A (fr) 1976-10-04
NL940007I1 (nl) 1994-06-01
HU179401B (en) 1982-10-28
IE42969B1 (en) 1980-11-19
DE2614406C2 (cs) 1992-02-20
FI62087B (fi) 1982-07-30
FR2305986A1 (fr) 1976-10-29
CA1076571A (en) 1980-04-29
FI62087C (fi) 1982-11-10
NL189199B (nl) 1992-09-01
CH622261A5 (cs) 1981-03-31
ES459348A1 (es) 1978-03-16
NL7504075A (nl) 1976-10-07
FR2305986B1 (cs) 1980-06-13
ES446634A1 (es) 1977-11-01
ZA761756B (en) 1977-03-30
DK142676A (cs) 1976-10-06
US4062848A (en) 1977-12-13
AU1236176A (en) 1977-09-29
DE2614406A1 (de) 1976-10-14
DK142498C (cs) 1981-07-06
JPS51122099A (en) 1976-10-25
SE7603931L (sv) 1976-10-06
GB1543171A (en) 1979-03-28
FI760884A7 (cs) 1976-10-06
NL189199C (nl) 1993-02-01

Similar Documents

Publication Publication Date Title
SE422941B (sv) Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar
SE433208B (sv) Forfarande for framstellning av fenoletrar
DK146205C (da) Analogifremgangsmaade til fremstilling af 8alfa-ergolin-i-derivater
SE438853B (sv) Forfarande for framstellning av 2-azetidinonforeningar
SE7605139L (sv) Forfarande for framstellning av vattenupptagande cellulosaetrar
SE430336B (sv) Forbettrat forfarande for framstellning av amoxicillinfrihydrat
SE427839B (sv) Analogiforfaranden for framstellning av n-aryl-n-(1-l-4-piperidinyl)-aryl-acetamider
NO139555C (no) Fremgangsmaate for fremstilling av fosgen
NO146058C (no) Analogifremgangsmaate for fremstilling av substituerte benzamider
SE443142B (sv) Forfarande for framstellning av rifamycinforeningar
SE7606116L (sv) Forfarande for framstellning av 3-fenoxidbensaldehyder
SE427841B (sv) Analogiforfarande for framstellning av tienamycinderivat
SE7604781L (sv) Forfarande for framstellning av diarylhydroxibutylaminer
SE404186B (sv) Forfarande for framstellning av cyklopropanolderivat
SE421793B (sv) Analogiforfarande for framstellning naftyridinsubstituerade pyrrolderivat
NO149137C (no) Analogifremgangsmaate ved fremsilling av diazepin-forbindelser
SE423814B (sv) Forfarande for framstellning av dibensofenazin- eller acenaftokinoxalinderivat
SE427840B (sv) Analogiforfarande for framstellning av tienamycinderivat
SE7610637L (sv) Forfarande for framstellning av 2-alkylindaner
SE446726B (sv) Forfarande for framstellning av 16-metoxiprostaglandiner
SE420730B (sv) Analogiforfarande for framstellning av nya pentacykliska foreningar
DK142845C (da) Analogifremgangsmaade til fremstilling af imidazolderivater
DK140476A (da) Fremgangsmade til fremstilling af trans-decalinderivater
SE7605427L (sv) Forfarande for framstellning av klorcyan
SE7603682L (sv) Forfarande for framstellning av en eteriskt substituerad monosackarid

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7603931-2

Format of ref document f/p: F

SPCF Application for supplementary protection certificate filed

Free format text: 9690008, 960228

NUG Patent has lapsed

Ref document number: 7603931-2

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9690008, 960228, EXPIRES: 20010402